{"id":390081,"date":"2020-11-30T18:03:05","date_gmt":"2020-11-30T23:03:05","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=390081"},"modified":"2020-11-30T18:03:05","modified_gmt":"2020-11-30T23:03:05","slug":"celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/","title":{"rendered":"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li><b>USD 278 million deal signed to secure 18 small molecule pharmaceutical product brand patents, trademarks, permits and sales rights in 9 Asia Pacific countries including South Korea<\/b><\/li>\n<li><b>Increased global sales capacity to build continuous growth momentum in the Asia Pacific market\u2014a stepping stone for Celltrion group to be an integrated global biopharmaceutical firm<\/b><\/li>\n<\/ul>\n<p>\n\u00a0\n<\/p>\n<p>INCHEON, South Korea&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.celltrion.com%2F&amp;esheet=52339246&amp;newsitemid=20201130005459&amp;lan=en-US&amp;anchor=Celltrion&amp;index=1&amp;md5=08fd8de5dc5188a120efaa2948d04d36\">Celltrion<\/a> (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) in Asia Pacific, igniting efforts to strengthen its R&amp;D capability in the global small molecule pharmaceuticals business.\n<\/p>\n<p>\nIn June, the firms announced an agreement under which Celltrion would acquire 18 &#8220;Primary Care&#8221; product assets in the Asia Pacific area for a total of USD 278 million inclusive of milestone payments from Takeda. Celltrion proceeded with the acquisition process through its newly established subsidiary in Singapore, &#8220;Celltrion Asia Pacific Pte, Ltd.&#8221;<sup>1<\/sup> (&#8220;Celltrion APAC&#8221;).\n<\/p>\n<p>\nUpon completion of the acquisition, Celltrion APAC will assume the ownership of the rights to patents, trademarks, and sales of 18 products sold in 9 markets including South Korea, Thailand, Taiwan, Hong Kong, Macau, the Philippines, Singapore, Malaysia, and Australia.\n<\/p>\n<p>\nThe 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Edarbi (hypertension) which were developed for global market, as well as OTC (Over-the-counter) products well known to consumers such as Whituben (cold remedy). Nesina and Edarbi in particular are expected to contribute to a stable revenue growth as the product patents will be protected until 2026 and 2027, respectively.\n<\/p>\n<p>\nCelltrion Pharm, a Celltrion subsidiary, will be a primary domestic distributor, while Celltrion Healthcare will distribute internationally, leveraging its sales networks in Southeast Asia and Australia. Celltrion has entered into a manufacturing and supply agreement with Takeda who will continue to manufacture the divested products for stable product supply and some of the products for local and international market will be manufactured at Celltrion Pharm\u2019s cGMP production facilities in future.\n<\/p>\n<p>\nThe acquisition provides Celltrion group an opportunity to strengthen its small molecule pharmaceutical product portfolio and progress towards a market leading position as a global biopharmaceutical company.\n<\/p>\n<p>\nCelltrion group also expects this transaction to help position itself as a stable supplier of high-quality, made-in-Korea original drugs and contribute to the reinforced financial strength of the national health system.\n<\/p>\n<p>\nBased on its own R&amp;D capacities and to-be acquired product patents, Celltrion plans to speed up the development of new medicines such as extended-release drugs and compound drugs, as well as biosimilar insulins to complete the portfolio of diabetic and hypertensive pipelines.\n<\/p>\n<p>\nCelltrion CEO Kee Woosung said &#8220;With the successful acquisition of select primary care and OTC product assets from Takeda in Asia Pacific Celltrion has set an important opportunity to develop additional new drugs and expand its market share in the region,&#8221; and &#8220;Celltrion will also do its best to secure a leading position in the Asia Pacific market and provide high quality medical products in the region.&#8221;\n<\/p>\n<p><b>About Celltrion, Inc<\/b><\/p>\n<p>\nHeadquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacturing of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC\u2019s approval for Inflectra\u00ae and Remsima\u00ae, respectively, which is the world\u2019s first mAb biosimilar to receive approval from a regulatory agency in a developed country. Also Celltrion received FDA and EC\u2019s approval for Truxima\u00ae and Herzuma\u00ae. Its products are manufactured at state-of-the-art mammalian cell culture facilities, designed and built to comply with the US FDA cGMP and the EU GMP guidelines.\n<\/p>\n<hr \/>\n<p><sup>1<\/sup> Celltrion Asia Pacific PtE. Ltd.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201130005459\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201130005459\/en\/<\/a><\/span><\/p>\n<p>\nCelltrion, Inc.<br \/>\n<br \/>Eunyoung Lee, +82 32 850 4384<br \/>\n<br \/><span class=\"bwuline\"><a rel=\"nofollow\" href=\"mailto:Eunyoung.lee1@celltrion.com\">Eunyoung.lee1@celltrion.com<\/a><\/span><br \/>Or<br \/>\n<br \/>Tae-Gyun Kim, +82 32 850 5136<br \/>\n<br \/><span class=\"bwuline\"><a rel=\"nofollow\" href=\"mailto:Taegyun.kim@celltrion.com\">Taegyun.kim@celltrion.com<\/a><\/span><\/p>\n<p><b>KEYWORDS:<\/b> Singapore North America Asia Pacific Japan Canada Europe United States South Korea<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Other Manufacturing Research Diabetes Manufacturing Biotechnology Health Pharmaceutical General Health Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201130005459\/en\/630213\/3\/celltrion_CI.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited USD 278 million deal signed to secure 18 small molecule pharmaceutical product brand patents, trademarks, permits and sales rights in 9 Asia Pacific countries including South Korea Increased global sales capacity to build continuous growth momentum in the Asia Pacific market\u2014a stepping stone for Celltrion group to be an integrated global biopharmaceutical firm \u00a0 INCHEON, South Korea&#8211;(BUSINESS WIRE)&#8211;Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) in Asia Pacific, igniting efforts to strengthen its R&amp;D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-390081","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited USD 278 million deal signed to secure 18 small molecule pharmaceutical product brand patents, trademarks, permits and sales rights in 9 Asia Pacific countries including South Korea Increased global sales capacity to build continuous growth momentum in the Asia Pacific market\u2014a stepping stone for Celltrion group to be an integrated global biopharmaceutical firm \u00a0 INCHEON, South Korea&#8211;(BUSINESS WIRE)&#8211;Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) in Asia Pacific, igniting efforts to strengthen its R&amp;D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would &hellip; Continue reading &quot;Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-30T23:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited\",\"datePublished\":\"2020-11-30T23:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/\"},\"wordCount\":689,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/\",\"name\":\"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-30T23:03:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/","og_locale":"en_US","og_type":"article","og_title":"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited - Market Newsdesk","og_description":"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited USD 278 million deal signed to secure 18 small molecule pharmaceutical product brand patents, trademarks, permits and sales rights in 9 Asia Pacific countries including South Korea Increased global sales capacity to build continuous growth momentum in the Asia Pacific market\u2014a stepping stone for Celltrion group to be an integrated global biopharmaceutical firm \u00a0 INCHEON, South Korea&#8211;(BUSINESS WIRE)&#8211;Celltrion (KRX:068270) has completed the acquisition of select primary care assets from Takeda Pharmaceutical Company Limited (\u201cTakeda\u201d) in Asia Pacific, igniting efforts to strengthen its R&amp;D capability in the global small molecule pharmaceuticals business. In June, the firms announced an agreement under which Celltrion would &hellip; Continue reading \"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-30T23:03:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited","datePublished":"2020-11-30T23:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/"},"wordCount":689,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/","name":"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-30T23:03:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201130005459r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/celltrion-completes-acquisition-of-primary-care-pc-product-assets-for-asia-pacific-markets-from-takeda-pharmaceutical-company-limited\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/390081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=390081"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/390081\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=390081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=390081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=390081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}